TY - JOUR
T1 - SARS-CoV-2 pathophysiology and its clinical implications
T2 - An integrative overview of the pharmacotherapeutic management of COVID-19
AU - Tsatsakis, Aristides
AU - Calina, Daniela
AU - Falzone, Luca
AU - Petrakis, Dimitrios
AU - Mitrut, Radu
AU - Siokas, Vasileios
AU - Pennisi, Manuela
AU - Lanza, Giuseppe
AU - Libra, Massimo
AU - Doukas, Sotirios G.
AU - Doukas, Panagiotis G.
AU - Kavali, Leena
AU - Bukhari, Amar
AU - Gadiparthi, Chiranjeevi
AU - Vageli, Dimitra P.
AU - Kofteridis, Diamantis P.
AU - Spandidos, Demetrios A.
AU - Paoliello, Monica M.B.
AU - Aschner, Michael
AU - Docea, Anca Oana
N1 - Funding Information:
The present study was supported in part by grants from the national Institute of Environmental Health Sciences (NIEHS) R01ES10563 and R01ES07331 (to MA).
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/12
Y1 - 2020/12
N2 - Common manifestations of COVID-19 are respiratory and can extend from mild symptoms to severe acute respiratory distress. The severity of the illness can also extend from mild disease to life-threatening acute respiratory distress syndrome (ARDS). SARS-CoV-2 infection can also affect the gastrointestinal tract, liver and pancreatic functions, leading to gastrointestinal symptoms. Moreover, SARS-CoV-2 can cause central and peripheral neurological manifestations, affect the cardiovascular system and promote renal dysfunction. Epidemiological data have indicated that cancer patients are at a higher risk of contracting the SARS-CoV-2 virus. Considering the multitude of clinical symptoms of COVID-19, the objective of the present review was to summarize their pathophysiology in previously healthy patients, as well as in those with comorbidities. The present review summarizes the current, though admittedly fluid knowledge on the pathophysiology and symptoms of COVID-19 infection. Although unclear issues still remain, the present study contributes to a more complete understanding of the disease, and may drive the direction of new research. The recognition of the severity of the clinical symptoms of COVID-19 is crucial for the specific therapeutic management of affected patients.
AB - Common manifestations of COVID-19 are respiratory and can extend from mild symptoms to severe acute respiratory distress. The severity of the illness can also extend from mild disease to life-threatening acute respiratory distress syndrome (ARDS). SARS-CoV-2 infection can also affect the gastrointestinal tract, liver and pancreatic functions, leading to gastrointestinal symptoms. Moreover, SARS-CoV-2 can cause central and peripheral neurological manifestations, affect the cardiovascular system and promote renal dysfunction. Epidemiological data have indicated that cancer patients are at a higher risk of contracting the SARS-CoV-2 virus. Considering the multitude of clinical symptoms of COVID-19, the objective of the present review was to summarize their pathophysiology in previously healthy patients, as well as in those with comorbidities. The present review summarizes the current, though admittedly fluid knowledge on the pathophysiology and symptoms of COVID-19 infection. Although unclear issues still remain, the present study contributes to a more complete understanding of the disease, and may drive the direction of new research. The recognition of the severity of the clinical symptoms of COVID-19 is crucial for the specific therapeutic management of affected patients.
KW - COVID-19 pandemic
KW - Cancer
KW - Cardiovascular system
KW - Clinical signs
KW - Gastrointestinal system
KW - Neurological system
KW - Pulmonary system
KW - SARS-C0V-2
UR - http://www.scopus.com/inward/record.url?scp=85091762227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091762227&partnerID=8YFLogxK
U2 - 10.1016/j.fct.2020.111769
DO - 10.1016/j.fct.2020.111769
M3 - Article
C2 - 32979398
AN - SCOPUS:85091762227
SN - 0278-6915
VL - 146
JO - Food and Chemical Toxicology
JF - Food and Chemical Toxicology
M1 - 111769
ER -
